-+ 0.00%
-+ 0.00%
-+ 0.00%

VERRICA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS

Reuters·01/07/2026 13:00:05

Please log in to view news